Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Fibrosis, and Genetic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for COL4A1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | COL4A1 Recombinant Protein (NC1 Domain / ECD) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for post-translational modifications. |
View COL4A1 Products |
| Gene Delivery | COL4A1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View COL4A1 Products |
| Benchmark Ab | Anti-COL4A1 Recombinant Antibody Recombinant positive control for validation and IHC/ELISA assays. |
View COL4A1 Products |
| Validator | COL4A1 siRNA Set For knockdown verification in functional assays. |
View COL4A1 Products |
| Related Target A | ITGA1 (Integrin Alpha-1) Primary cell-surface receptor mediating cell adhesion to collagen IV. |
View ITGA1 Products |
| Related Target B | TGFB1 (Transforming Growth Factor Beta 1) Key upstream driver of COL4A1 expression in fibrotic diseases. |
View TGFB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex triple-helix conformation and solubility issues | HEK293 expressed soluble NC1 domains and truncated ECD-Fc fusions with verified sequence and theoretical MW. |
| Cross-reactivity within the Collagen IV family (COL4A2-A6) | High-purity homolog panel proteins strictly verified by mass spectrometry to ensure assay specificity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live COL4A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Collagen Type IV Alpha 1 (COL4A1) is emerging as a critical frontier in both oncology and fibrotic disease management. As a major structural component of the basement membrane, COL4A1 undergoes significant remodeling in the tumor microenvironment (TME) and fibrotic organs. The race for COL4A1 therapeutics is intensifying, with major players shifting focus from traditional systemic extracellular matrix (ECM) disruption to highly targeted monoclonal antibodies, small molecule inhibitors of collagen cross-linking, and siRNA-based silencing. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific neo-epitopes and integrin-binding domains to avoid systemic basement membrane toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Oncology-focused Biotechs, Academic Consortia | Solid Tumors (Gastric, Colorectal, Glioblastoma) | Epitope mapping and binding affinity assays (Need high-purity, native-glycosylated ECD-Fc) |
| siRNA / ASOs | RNAi Therapeutics Specialists | Renal Fibrosis, Hepatic Fibrosis, HANAC Syndrome | In vitro knockdown validation (Need sequence-verified siRNA sets and Lentivirus for stable lines) |
| Small Molecules / Peptides | Fibrosis-focused Biotechs | Organ Fibrosis, Angiogenesis-driven Diseases | Integrin-blocking and cell adhesion assays (Need functional integrin heterodimers like ITGA1/ITGB1) |